Quinoxaline-based anti-schistosomal compounds have potent anti-plasmodial activity

Abstract excerpt

The human pathogens Plasmodium and Schistosoma are each responsible for over 200 million infections annually, especially in low- and middle-income countries. There is a pressing need for new drug targets for these diseases, driven by emergence of drug-resistance in Plasmodium and an overall dearth of drug targets against Schistosoma. Here, we explored the opportunity for pathogen-hopping by evaluating a series of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Malaria Research and Control
• Share to Parasites and Host Interactions
• Share to Research on Leishmaniasis Studies